RESUMO
The discovery of insulin in 1921 enabled pharmaceutical production of animal insulins for the treatment of people with type 1 diabetes by 1922. The last several decades have witnessed enormous scientific progress in the therapy of type 1 diabetes, yet some developments have been incremental, and insulin is not a cure. Herein, I highlight key scientific advances potentially poised to improve the quality of life and treatment outcomes in type 1 diabetes. These innovations range from newer insulin analogues to the development of smart insulins, oral and weekly insulins, glucose sensors and closed-loop insulin-delivery devices, as well as strategies for durable human beta cell replacement coupled with selective immune manipulation to preserve beta cell function. Finally, progress in the prediction and prevention of type 1 diabetes highlights the ongoing challenges and potential for altering the natural history of the disease or eliminating type 1 diabetes altogether.
Assuntos
Diabetes Mellitus Tipo 1/terapia , Invenções/tendências , Glicemia/análise , Glicemia/metabolismo , Automonitorização da Glicemia/instrumentação , Automonitorização da Glicemia/tendências , Diabetes Mellitus Tipo 1/sangue , Diabetes Mellitus Tipo 1/epidemiologia , Humanos , Insulina/administração & dosagem , Sistemas de Infusão de Insulina/tendências , Pâncreas Artificial/tendências , Resultado do TratamentoAssuntos
Automonitorização da Glicemia/tendências , COVID-19/epidemiologia , Países em Desenvolvimento , Diabetes Mellitus/epidemiologia , Educação de Pacientes como Assunto/tendências , Telemedicina/tendências , Automonitorização da Glicemia/economia , COVID-19/economia , Diabetes Mellitus/sangue , Diabetes Mellitus/economia , Humanos , Pandemias , Educação de Pacientes como Assunto/economia , Telemedicina/economiaRESUMO
DISCLOSURES: No outside funding supported the writing of this letter. The author has nothing to disclose.
Assuntos
Automonitorização da Glicemia/tendências , Glicemia/metabolismo , Índice Glicêmico/fisiologia , Política de Saúde/tendências , Farmacêuticos/tendências , Atenção Primária à Saúde/tendências , Índice Glicêmico/efeitos dos fármacos , Humanos , Papel ProfissionalRESUMO
In past decades, a rapid evolution of diabetes technology led to increased popularity and use of continuous glucose monitoring (CGM) and continuous subcutaneous insulin infusion (CSII) in the ambulatory setting for diabetes management, and recently, the artificial pancreas became available. Efforts to translate this technology to the hospital setting have shown accuracy and reliability of CGM, safety of CSII in appropriate populations, improvement of inpatient glycemic control with computerized glycemic management systems, and feasibility of inpatient CGM-CSII closed-loop systems. Several ongoing studies are focusing on continued translation of this technology to improve glycemic control and outcomes in hospitalized patients.
Assuntos
Diabetes Mellitus/terapia , Hospitalização , Hiperglicemia/terapia , Invenções , Glicemia/análise , Automonitorização da Glicemia/história , Automonitorização da Glicemia/instrumentação , Automonitorização da Glicemia/tendências , Diabetes Mellitus/sangue , Diabetes Mellitus/tratamento farmacológico , Diabetes Mellitus/história , História do Século XX , História do Século XXI , Hospitalização/tendências , Humanos , Hiperglicemia/sangue , Hiperglicemia/tratamento farmacológico , Hiperglicemia/história , Pacientes Internados , Insulina/administração & dosagem , Sistemas de Infusão de Insulina/história , Sistemas de Infusão de Insulina/provisão & distribuição , Sistemas de Infusão de Insulina/tendências , Invenções/história , Invenções/tendências , Pâncreas Artificial/história , Pâncreas Artificial/provisão & distribuiçãoAssuntos
Diabetes Mellitus , Invenções/tendências , Adulto , Automonitorização da Glicemia/história , Automonitorização da Glicemia/instrumentação , Automonitorização da Glicemia/tendências , Criança , Diabetes Mellitus/sangue , Diabetes Mellitus/tratamento farmacológico , História do Século XXI , Humanos , Insulina/administração & dosagem , Sistemas de Infusão de Insulina/história , Sistemas de Infusão de Insulina/provisão & distribuição , Sistemas de Infusão de Insulina/tendências , Invenções/história , Pâncreas Artificial/história , Pâncreas Artificial/provisão & distribuição , Pâncreas Artificial/tendênciasRESUMO
Technological innovations have fundamentally changed diabetes care. Insulin pump use and continuous glucose monitoring are associated with improved glycemic control along with a better quality of life; automated insulin-dosing advisors facilitate and improve decision making. Glucose-responsive automated insulin delivery enables the highest targets for time in range, lowest rate and duration of hypoglycemia, and favorable quality of life. Clear targets for time in ranges and a standard visualization of the data will help the diabetes technology to be used more efficiently. Decision support systems within and integrated cloud environment will further simplify, unify, and improve modern routine diabetes care.
Assuntos
Diabetes Mellitus Tipo 1 , Invenções/tendências , Automonitorização da Glicemia/instrumentação , Automonitorização da Glicemia/tendências , Sistemas de Apoio a Decisões Clínicas/instrumentação , Sistemas de Apoio a Decisões Clínicas/tendências , Diabetes Mellitus Tipo 1/sangue , Diabetes Mellitus Tipo 1/tratamento farmacológico , Equipamentos e Provisões , Humanos , Injeções Subcutâneas/instrumentação , Injeções Subcutâneas/tendências , Insulina/administração & dosagem , Sistemas de Infusão de Insulina/tendências , Pâncreas Artificial/tendênciasRESUMO
The current era has witnessed an explosion of advanced diabetes technologies. Young people with diabetes and their families require detailed, structured diabetes education in order to optimize use of such devices. There is need for youth and their families to participate in the selection of particular devices for personal use and comprehensive education regarding the safe and effective use of such technologies. The education process should ensure that youth and their families receive realistic expectations of what the advanced technologies can and cannot do to avoid disappointment and the premature discontinuation of such systems.
Assuntos
Diabetes Mellitus Tipo 1 , Invenções , Educação de Pacientes como Assunto , Adolescente , Fatores Etários , Automonitorização da Glicemia/instrumentação , Automonitorização da Glicemia/métodos , Automonitorização da Glicemia/tendências , Cuidadores/educação , Criança , Pré-Escolar , Diabetes Mellitus Tipo 1/sangue , Diabetes Mellitus Tipo 1/tratamento farmacológico , Família/psicologia , Humanos , Hipoglicemiantes/administração & dosagem , Insulina/administração & dosagem , Sistemas de Infusão de Insulina/tendências , Invenções/tendências , Educação de Pacientes como Assunto/métodos , Educação de Pacientes como Assunto/organização & administração , Educação de Pacientes como Assunto/tendências , Autocuidado/métodos , Autogestão/educação , Autogestão/métodos , Autogestão/tendênciasRESUMO
In the last 2 decades, diabetes technology has emerged as a branch of diabetes management thanks to the advent of continuous glucose monitoring (CGM) and increased availability of continuous subcutaneous insulin infusion systems, or insulin pumps. These tools have progressed from rudimentary instruments to sophisticated therapeutic options for advanced diabetes management. This article discusses the available CGM and insulin pump systems and the clinical benefits of their use in adults with type 1 diabetes, intensively insulin-treated type 2 diabetes, and pregnant patients with preexisting diabetes.
Assuntos
Diabetes Mellitus Tipo 1 , Diabetes Mellitus Tipo 2 , Invenções , Adulto , Automonitorização da Glicemia/história , Automonitorização da Glicemia/instrumentação , Automonitorização da Glicemia/métodos , Automonitorização da Glicemia/tendências , Diabetes Mellitus Tipo 1/sangue , Diabetes Mellitus Tipo 1/tratamento farmacológico , Diabetes Mellitus Tipo 2/sangue , Diabetes Mellitus Tipo 2/tratamento farmacológico , Feminino , História do Século XX , História do Século XXI , Humanos , Insulina/administração & dosagem , Sistemas de Infusão de Insulina/história , Sistemas de Infusão de Insulina/tendências , Invenções/história , Invenções/tendências , Gravidez , Gravidez em Diabéticas/sangue , Gravidez em Diabéticas/tratamento farmacológicoRESUMO
With successful aging of adults with type 1 diabetes, there is an increased opportunity to use technology for diabetes management. Technology can ease the burden of self-care and provide a sense of security. However, age-related cognitive and physical decline can make technology use difficult. Guidelines using technology in the aging population are urgently needed, along with educational material for the clinicians and caregivers. In this article, we review the evidence supporting the use of diabetes-related technologies in the older population and discuss recommendations based on current data and the authors' clinical knowledge and experience.
Assuntos
Envelhecimento/fisiologia , Diabetes Mellitus Tipo 1 , Diabetes Mellitus Tipo 2 , Invenções/tendências , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Envelhecimento/psicologia , Glicemia/análise , Automonitorização da Glicemia/instrumentação , Automonitorização da Glicemia/tendências , Diabetes Mellitus Tipo 1/sangue , Diabetes Mellitus Tipo 1/tratamento farmacológico , Diabetes Mellitus Tipo 1/epidemiologia , Diabetes Mellitus Tipo 2/sangue , Diabetes Mellitus Tipo 2/tratamento farmacológico , Diabetes Mellitus Tipo 2/epidemiologia , Conhecimentos, Atitudes e Prática em Saúde , Humanos , Insulina/administração & dosagem , Sistemas de Infusão de Insulina/tendências , Medição de RiscoRESUMO
This article attempts to aid clinicians in using diabetes devices in their clinical practice. It reviews device selection, initiation, and follow-up. It discusses work flow in an office and provides tips on billing. It stresses the need for patient choice, education, and on-going support through downloading and interpretation of data to optimize care.
Assuntos
Diabetes Mellitus , Conhecimentos, Atitudes e Prática em Saúde , Invenções , Padrões de Prática Médica , Atitude Frente aos Computadores , Glicemia/análise , Automonitorização da Glicemia/instrumentação , Automonitorização da Glicemia/métodos , Automonitorização da Glicemia/tendências , Comportamento de Escolha , Tomada de Decisões/fisiologia , Diabetes Mellitus/sangue , Diabetes Mellitus/tratamento farmacológico , Humanos , Insulina/administração & dosagem , Sistemas de Infusão de Insulina/tendências , Invenções/tendências , Educação de Pacientes como Assunto , Papel do Médico , Padrões de Prática Médica/tendênciasRESUMO
The American Diabetes Association (ADA) "Standards of Medical Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc20-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc20-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Assuntos
Diabetes Mellitus/terapia , Invenções/normas , Automonitorização da Glicemia/instrumentação , Automonitorização da Glicemia/métodos , Automonitorização da Glicemia/tendências , Diabetes Mellitus/sangue , Diabetes Mellitus/epidemiologia , Endocrinologia/instrumentação , Endocrinologia/métodos , Endocrinologia/organização & administração , Endocrinologia/normas , Equipamentos e Provisões/normas , História do Século XXI , Humanos , Insulina/administração & dosagem , Sistemas de Infusão de Insulina/normas , Invenções/história , Invenções/tendências , Padrões de Referência , Sociedades Médicas/organização & administração , Sociedades Médicas/normas , Padrão de Cuidado/história , Padrão de Cuidado/normas , Estados Unidos/epidemiologiaRESUMO
OBJECTIVE: Intensive self-monitoring of blood glucose levels by patients with diabetes achieves optimal glucose control, hence reducing the likelihood of complications. METHODS: This is a prospective, cross-sectional study targeting adults with diabetes through community pharmacies and patient groups in Central and West London over a period of 10 weeks. RESULTS: In all, 195 adults with diabetes were included in the analysis of the results. When monitoring adherence was examined, 43.4% (n=33/76) of participants with type 1 diabetes reported that their health care professionals had asked them to monitor their blood glucose levels between 3 and 4 times per day; however, 10% of this group was not following their health-care professionals' directions. Participants with type 2 diabetes were asked the same question; 42.9% (n=51/119) were asked to monitor their blood glucose between 3 and 4 times a day, but only 2.5% (n=3/119) were following their health-care professionals' directions. When questioned about their reasons for poor adherence, the cohort indicated that it was due to the painful (29.2%, n=57/195), uncomfortable (33.8%, n=66/195) or inconvenient (36.9%, n=72/195) nature of testing. In addition, 75.3% (n=147/195) of the participants expressed their desire for a noninvasive monitoring device, and 74.3% (n=145/195) said they would be satisfied to use one of the preselected advanced technologies to monitor their blood glucose levels. CONCLUSIONS: The favoured advanced technology, selected by 49.7% (n=97/195) of participants, was the wristband. Statistical significance was seen between the type of diabetes and the device selected; patients with type 1 diabetes preferred contact lenses (p<0.05) and tattoos (p<0.0001), whereas participants with type 2 diabetes preferred earlobe sensors (p<0.0001) and saliva analyzers (p<0.0001). Participants' gender, age and ethnicity also influenced device selection.
Assuntos
Glicemia/metabolismo , Diabetes Mellitus Tipo 1/sangue , Diabetes Mellitus Tipo 2/sangue , Invenções , Participação do Paciente , Percepção , Adulto , Automonitorização da Glicemia/psicologia , Automonitorização da Glicemia/tendências , Estudos Transversais , Diabetes Mellitus Tipo 1/epidemiologia , Diabetes Mellitus Tipo 1/psicologia , Diabetes Mellitus Tipo 2/epidemiologia , Diabetes Mellitus Tipo 2/psicologia , Feminino , Humanos , Londres/epidemiologia , Masculino , Pessoa de Meia-Idade , Participação do Paciente/psicologia , Estudos Prospectivos , Inquéritos e Questionários , Adulto JovemRESUMO
The primary objective of this study was to analyze the most up-to-date evidence regarding whether and how blood sugar regulation influences cardiovascular health promotion and disease prevention by carrying out an umbrella review. Three separate, systematic literature searches identified 2,343 papers in total. Overall, 44 studies were included for data extraction and analysis. The included systematic reviews and meta-analyses published between January 1, 2016, and December 31, 2017, were of good to very good quality (median Overview Quality Assessment Questionnaire score = 17). Identified evidence suggests that cardiovascular disease (CVD) prevention services should consider regulation of blood glucose as a key target for intervention. Furthermore, the recommendations for effective intervention and service development/training described here for prevention of CVD should be adopted into evidence-based practice guidelines. Multidisciplinary teams should be formed to deliver multicomponent interventions in community-based settings. There may be substantial opportunities for integrating CVD and diabetes prevention services.
Assuntos
Glicemia/metabolismo , Doenças Cardiovasculares/sangue , Doenças Cardiovasculares/prevenção & controle , Diabetes Mellitus/sangue , Promoção da Saúde/métodos , Automonitorização da Glicemia/métodos , Automonitorização da Glicemia/tendências , Doenças Cardiovasculares/fisiopatologia , Diabetes Mellitus/fisiopatologia , Diabetes Mellitus/terapia , Promoção da Saúde/tendências , Humanos , Prevenção Primária/métodos , Prevenção Primária/tendênciasRESUMO
Type 1 diabetes mellitus (T1DM) represents 5-10% of diabetes cases worldwide. The incidence of T1DM is increasing, and there is no immediate prospect of a cure. As such, lifelong management is required, the burden of which is being eased by novel treatment modalities, particularly from the field of diabetes technologies. Continuous glucose monitoring has become the standard of care and includes factory-calibrated subcutaneous glucose monitoring and long-term implantable glucose sensing. In addition, considerable progress has been made in technology-enabled glucose-responsive insulin delivery. The first hybrid insulin-only closed-loop system has been commercialized, and other closed-loop systems are under development, including dual-hormone glucose control systems. This Review focuses on well-established diabetes technologies, including glucose sensing, pen-based insulin delivery, data management and data analytics. We also cover insulin pump therapy, threshold-based suspend, predictive low-glucose suspend and single-hormone and dual-hormone closed-loop systems. Clinical practice recommendations for insulin pump therapy and continuous glucose monitoring are presented, and ongoing research and future prospects are highlighted. We conclude that the management of T1DM is improved by diabetes technology for the benefit of the majority of people with T1DM, their caregivers and guardians and health-care professionals treating patients with T1DM.
Assuntos
Diabetes Mellitus Tipo 1/diagnóstico , Diabetes Mellitus Tipo 1/tratamento farmacológico , Sistemas de Infusão de Insulina , Insulina/administração & dosagem , Pâncreas Artificial , Tecnologia Biomédica , Glicemia/metabolismo , Automonitorização da Glicemia/normas , Automonitorização da Glicemia/tendências , Gerenciamento Clínico , Sistemas de Liberação de Medicamentos , Feminino , Previsões , Humanos , Insulina/farmacologia , Masculino , Melhoria de Qualidade , Índice de Gravidade de DoençaRESUMO
The advent of devices that can track interstitial glucose levels, which are closely related to blood glucose levels, on a near continuous basis, has facilitated better insights into patterns of glycaemia. Continuous glucose monitoring (CGM) therefore allows for more intensive monitoring of blood glucose levels and potentially improved glycaemic control. In the context of the announcement on 1 April 2017 that the Australian Government will fund CGM monitoring for people with type 1 diabetes under the age of 21 years, this paper provides a review of the evidence for CGM and some of the ongoing challenges. There is evidence that real-time CGM in type 1 diabetes improves HbA1c and hypoglycaemia, while in type 2 diabetes, the evidence is less robust. Initial barriers to widespread implementation of CGM included issues with accuracy and user friendliness; however, as the technology has evolved, these issues have largely improved. Ongoing barriers include cost, and weaker evidence for their benefit in certain populations such as those with type 2 diabetes and less glycaemic variability. CGM has the potential to reduce healthcare costs, although real-world studies, including cost-effectiveness analyses, are needed in this area.
Assuntos
Automonitorização da Glicemia/métodos , Glicemia/metabolismo , Diabetes Mellitus Tipo 1/sangue , Diabetes Mellitus Tipo 2/sangue , Automonitorização da Glicemia/economia , Automonitorização da Glicemia/tendências , Análise Custo-Benefício , Diabetes Mellitus Tipo 1/diagnóstico , Diabetes Mellitus Tipo 1/economia , Diabetes Mellitus Tipo 2/diagnóstico , Diabetes Mellitus Tipo 2/economia , Previsões , Índice Glicêmico/fisiologia , HumanosRESUMO
OBJECTIVES: To describe trends in blood glucose test strip (TS) utilization and cost in Saskatchewan. METHODS: A retrospective analysis of TS use between January 1, 1996, and December 31, 2013, was conducted using population-based health administrative databases in Saskatchewan. The prescription drug database was used to describe the annual number of TS dispensations, the number of strips dispensed, the number of unique beneficiaries and the total costs. A patient-level analysis was also carried out to describe the patterns of TS use (i.e. light, moderate or heavy) by the entire cohort and by diabetes treatments. Potential cost savings due to a newly implemented restriction policy were estimated based on the most recent data (2013). RESULTS: TS utilization increased dramatically between 1996 and 2013 in terms of the number of users and the average number of TSs received. The percentage of TS users receiving fewer than 4 TSs per week (i.e. light users) decreased by 20%, while the percentage of heavy users (i.e. those receiving more than 8 TSs per week) increased by 19%. During the same period, the use of high-risk oral hypoglycemic medications declined by 30% among all TS users. Heavy TS use was observed in at least one-third of all users, irrespective of treatment type. CONCLUSIONS: If Saskatchewan's newly imposed coverage limits had been applied in 2013, the costs of strips exceeding those limits would have totalled $2.5 million. Although TS use aligns with chronic disease care paradigms, the substantial costs and lack of evidence of patient outcomes demand better strategies to help reduce unnecessary use.
Assuntos
Automonitorização da Glicemia/estatística & dados numéricos , Automonitorização da Glicemia/tendências , Glicemia/análise , Diabetes Mellitus/sangue , Política de Saúde , Adolescente , Adulto , Automonitorização da Glicemia/economia , Redução de Custos , Diabetes Mellitus/diagnóstico , Diabetes Mellitus/tratamento farmacológico , Feminino , Humanos , Hipoglicemiantes/economia , Hipoglicemiantes/uso terapêutico , Masculino , Estudos Retrospectivos , Saskatchewan , Adulto JovemRESUMO
OBJECTIVES: Considerable attention has been paid to the rising costs of the use of blood glucose test strips (BGTS). Insulin users have generally been treated as a single homogeneous group, resulting in policies that cap usage (8.2 strips/day) in provincial drug insurance programs. The objective of this study was to conduct a utilization review of BGTS by insulin users and to evaluate use patterns against current insulin use patterns and BGTS policy. METHODS: BGTS usage was examined in a cohort of insulin users with type 1 and type 2 diabetes over a 12-year period (2001 to 2013) using the population-based administrative data in Manitoba, Canada. RESULTS: Total BGTS strip use increased by 121%, from $4.3 to $9.5 million. However, the number of insulin users also increased by 115%. Use has been stable at 1.5 strips per day per person since 2004 by insulin users with type 2 diabetes but has risen from 1.9 to 3.0 strips per day per person in those with type 1 diabetes. Mean daily test strip use was below the number of daily tests recommended for patients using insulin as per the current Canadian guidelines, with 11% and 15% of insulin users with type 1 and type 2 diabetes not claiming any BGTS use and a further 15% (type 1) and 28% (type 2) using fewer than 1 strip per day. CONCLUSIONS: BGTS use per insulin user has been stable for most of the past decade, and the vast majority of use falls well below provincial insurance caps. The amount of low-level testing (0 to <1 strip/day) suggests that greater attention should be directed to ensuring a safe level of testing by all insulin users.
Assuntos
Glicemia/metabolismo , Diabetes Mellitus/sangue , Política de Saúde/tendências , Insulina/uso terapêutico , Revisão da Utilização de Recursos de Saúde/tendências , Automonitorização da Glicemia/tendências , Estudos de Coortes , Diabetes Mellitus/diagnóstico , Diabetes Mellitus/tratamento farmacológico , Humanos , Estudos Longitudinais , Fitas Reagentes , Estudos Retrospectivos , Fatores de TempoRESUMO
OBJECTIVES: To evaluate the impact of new quantity limits for blood glucose test strips (BGTS) in August 2013 on utilization patterns and costs in the elderly population of Ontario, Canada. METHODS: We conducted a population-based, cross-sectional time series analysis of all individuals 65 years of age and older who received publically funded BGTSs between August 1, 2010, and July 31, 2015, in Ontario, Canada. The number of BGTSs dispensed and the associated costs were measured for 4 diabetes therapy subgroups-insulin, hypoglycemia-inducing oral agents, non-hypoglycemia-inducing oral agents, and no drug therapy-each month during the study period. We used interventional autoregressive integrated moving average (ARIMA) models to assess the impact of Ontario's policy change on test strip use and costs. RESULTS: In the course of the study period, 657,338,177 test strips were dispensed to elderly patients in Ontario, at a total cost of CAN$482.3 million. Introduction of quantity limits was associated with significant reductions in the number of monthly strips dispensed and the associated costs (p<0.0001). In the year following the policy's implementation, test strip use decreased by 22.2% compared with the prior year (from 145,232,024 test strips to 113,007,795 test strips, a net decrease of 32,224,229 strips), resulting in a 22.5% reduction in costs (from $106.5 million to $82.6 million, a net cost reduction of approximately $24 million). CONCLUSIONS: The introduction of quantity limits, aligned with guidance from the Canadian Diabetes Association, led to immediate significant reductions in BGTS dispensing and costs. More research is needed to assess the impact of this policy on patient outcomes.
Assuntos
Automonitorização da Glicemia/economia , Custos e Análise de Custo , Diabetes Mellitus/economia , Política de Saúde , Idoso , Idoso de 80 Anos ou mais , Glicemia , Automonitorização da Glicemia/instrumentação , Automonitorização da Glicemia/tendências , Redução de Custos , Humanos , OntárioRESUMO
AIM: To determine the cost-effectiveness of all options for the self-monitoring of blood glucose funded by the National Health Service, providing guidance for disinvestment and testing the hypothesis that advanced meter features may justify higher prices. METHODS: Using data from the Health and Social Care Information Centre concerning all 8 340 700 self-monitoring of blood glucose-related prescriptions during 2013/2014, we conducted a cost-minimization analysis, considering both strip and lancet costs, including all clinically equivalent technologies for self-monitoring of blood glucose, as determined by the ability to meet ISO-15197:2013 guidelines for meter accuracy. RESULTS: A total of 56 glucose monitor, test strip and lancet combinations were identified, of which 38 met the required accuracy standards. Of these, the mean (range) net ingredient costs for test strips and lancets were £0.27 (£0.14-£0.32) and £0.04 (£0.02-£0.05), respectively, resulting in a weighted average of £0.28 (£0.18-£0.37) per test. Systems providing four or more advanced features were priced equal to those providing just one feature. A total of £12 m was invested in providing 42 million self-monitoring of blood glucose tests with systems that fail to meet acceptable accuracy standards, and efficiency savings of £23.2 m per annum are achievable if the National Health Service were to disinvest from technologies providing lesser functionality than available alternatives, but at a much higher price. CONCLUSION: The study uncovered considerable variation in the price paid by the National Health Service for self-monitoring of blood glucose, which could not be explained by the availability of advanced meter features. A standardized approach to self-monitoring of blood glucose prescribing could achieve significant efficiency savings for the National Health Service, whilst increasing overall utilisation and improving safety for those currently using systems that fail to meet acceptable standards for measurement accuracy.
Assuntos
Automonitorização da Glicemia , Redução de Custos , Diabetes Mellitus/sangue , Custos de Cuidados de Saúde , Reforma dos Serviços de Saúde , Promoção da Saúde , Modelos Econômicos , Automonitorização da Glicemia/efeitos adversos , Automonitorização da Glicemia/economia , Automonitorização da Glicemia/instrumentação , Automonitorização da Glicemia/tendências , Terapia Combinada/economia , Terapia Combinada/instrumentação , Terapia Combinada/tendências , Custos e Análise de Custo , Diabetes Mellitus/economia , Diabetes Mellitus/terapia , Reforma dos Serviços de Saúde/economia , Promoção da Saúde/economia , Humanos , Hiperglicemia/diagnóstico , Hiperglicemia/economia , Hiperglicemia/prevenção & controle , Hipoglicemia/diagnóstico , Hipoglicemia/economia , Hipoglicemia/prevenção & controle , Guias de Prática Clínica como Assunto , Prescrições , Melhoria de Qualidade/economia , Qualidade da Assistência à Saúde , Fitas Reagentes/economia , Reprodutibilidade dos Testes , Medicina Estatal , Reino UnidoRESUMO
Continuous subcutaneous insulin infusion was initially developed as a research procedure in the 1970s but quickly became a routine treatment for selected people with Type 1 diabetes. Continuous subcutaneous insulin infusion and other diabetes technologies, such as continuous glucose monitoring, are now an established and evidence-based part of diabetes care, but there has been some confusion about effectiveness and best use, particularly because of conflicting results from meta-analyses. This is because literature summary meta-analyses (including all trials) are inappropriate for therapeutic and economic decision-making; such meta-analyses should only include trials representative of groups likely to benefit. For example, for continuous subcutaneous insulin infusion, this would be those with continued disabling hypoglycaemia or elevated HbA1c levels. Alternatively, individual patient data meta-analysis allows modelling of covariates that determine effect size, e.g. in the case of continuous glucose monitoring, baseline HbA1c and frequency of sensor usage. Diabetes technology is therefore an example of personalized medicine, where evaluation and use should be both appropriate and targeted. This will also apply to future technologies such as new 'patch' pumps for Type 2 diabetes, closed-loop insulin delivery systems and nanomedicine applications in diabetes that we are currently researching. These include fluorescence lifetime-based non-invasive glucose monitoring and nanoencapsulation of islets for improved post-transplant survival.